1 unknown. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Unknown 1 |
Follow Asger Sverrild: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPD Tezepelumab, Placebo - COPD, COPD Exacerbation | Phase 2 | Unknown | Asger Sverrild | 80 | 2022-10-25 | 2024-08-21 |
Immune System Diseases (1) · Pulmonary Disease, Chronic Obstructive (1)
tezepelumab (1)
Denmark (1) · United Kingdom (1)